A real quickie today, because I know I'm behind on posting:
Cornell's excellent blog, New Developments in Lymphoma, has a new post on Obinutuzumab, also known as GA101 -- a "new generation Rituximab." (I've seen it called both a second-generation and third-generation monoclonal antibody; they were wise to just avoid that issue altogether.)
As the post explains, results from several studies have been in the news lately touting GA101's success. I' a big fan of Rituxan (closing in on two years since I had it successfully), but I'm all for improvements to it.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment